--- title: "Ironwood Pharmaceuticals, Inc. (IRWD.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/IRWD.US.md" symbol: "IRWD.US" name: "Ironwood Pharmaceuticals, Inc." industry: "Biotechnology" datetime: "2026-05-20T15:39:18.608Z" locales: - [en](https://longbridge.com/en/quote/IRWD.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/IRWD.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/IRWD.US.md) --- # Ironwood Pharmaceuticals, Inc. (IRWD.US) ## Company Overview Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [ironwoodpharma.com](https://ironwoodpharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:15.000Z **Overall: C (0.46)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 116 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 13.80% | | | Net Profit YoY | 415.90% | | | P/B Ratio | -2.78 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 604131200.02 | | | Revenue | 361514000.00 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -37.07% | E | | Profit Margin | 28.26% | A | | Gross Margin | 79.40% | A | | Revenue YoY | 13.80% | B | | Net Profit YoY | 415.90% | A | | Total Assets YoY | 32.81% | A | | Net Assets YoY | 35.00% | A | | Cash Flow Margin | 109.82% | C | | OCF YoY | 13.80% | B | | Turnover | 0.95 | A | | Gearing Ratio | 149.97% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Ironwood Pharmaceuticals, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "13.80%", "rating": "" }, { "name": "Net Profit YoY", "value": "415.90%", "rating": "" }, { "name": "P/B Ratio", "value": "-2.78", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "604131200.02", "rating": "" }, { "name": "Revenue", "value": "361514000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-37.07%", "rating": "E" }, { "name": "Profit Margin", "value": "28.26%", "rating": "A" }, { "name": "Gross Margin", "value": "79.40%", "rating": "A" }, { "name": "Revenue YoY", "value": "13.80%", "rating": "B" }, { "name": "Net Profit YoY", "value": "415.90%", "rating": "A" }, { "name": "Total Assets YoY", "value": "32.81%", "rating": "A" }, { "name": "Net Assets YoY", "value": "35.00%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "109.82%", "rating": "C" }, { "name": "OCF YoY", "value": "13.80%", "rating": "B" }, { "name": "Turnover", "value": "0.95", "rating": "A" }, { "name": "Gearing Ratio", "value": "149.97%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 5.91 | 19/386 | 27.24 | 23.25 | 18.92 | | PB | -2.78 | 501/386 | - | - | - | | PS (TTM) | 1.67 | 41/386 | 2.03 | 1.50 | 0.42 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-07T04:00:00.000Z Total Analysts: **4** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 25% | | Overweight | 1 | 25% | | Hold | 2 | 50% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 3.69 | | Highest Target | 10.00 | | Lowest Target | 3.70 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IRWD.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IRWD.US/norm.md) - [Related News](https://longbridge.com/en/quote/IRWD.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IRWD.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**